Moderna Aktie News

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the vaccine maker said on Friday.

Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing aut...

The retailer's stock could be experiencing a short squeeze.

The two collaborated on research showing that quantum computing could greatly aid the design of mRNA-based medicines and treatments.

Moderna said on Friday it is cancelling plans to build a messenger RNA manufacturing plant in Japan due to "changes in the business environment" around the world and in Japan.

Moderna's stock has faced heavy pressure from negative headlines, regulatory setbacks, and political uncertainty, but recent FDA approvals have stabilized sentiment. The company now boasts three approved respiratory vaccines, a strong cash position, and a robust pipeline, supporting a potential long-term growth narrative beyond COVID. Key risks remain: political headwinds, commercial execution,...

It's difficult to get motivated about buying a stock that's plummeted or a company that seems to be out of favor with the general investment community. But if that company has bright long-term prospects, it's a great idea to stop and take a closer look.

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago.